Notes · Pharmacology · 19 October 2026

Calcium Channel Blockers: Classification, Mechanism, Indications & Adverse Effec

Definition

Calcium channel blockers (CCBs) are a group of drugs that inhibit the influx of calcium ions through L‑type voltage‑gated calcium channels in cardiac myocytes, vascular smooth muscle, and the sino‑atrial (SA) and atrio‑ventricular (AV) nodes. By reducing intracellular calcium, they decrease myocardial contractility, slow conduction through the AV node, and cause vasodilation of arterioles.

Classification

CCBs are divided into two major chemical families, each with distinct vascular and cardiac effects:

Mechanism of Action (Step‑by‑Step)

1. Binding – The drug binds to the α1‑subunit of the L‑type calcium channel located on the cell membrane of vascular smooth muscle and cardiac cells.
2. Channel Closure – Binding stabilises the channel in its inactive conformation, preventing the voltage‑dependent opening that normally occurs during depolarisation.
3. Reduced Calcium Entry – With fewer channels open, extracellular calcium (Ca²⁺) cannot enter the cytoplasm during the plateau phase (phase 2) of the cardiac action potential or during smooth‑muscle depolarisation.
4. Decreased Intracellular Calcium – Lower intracellular Ca²⁺ reduces activation of calmodulin‑dependent myosin light‑chain kinase, the enzyme that phosphorylates myosin and initiates contraction.
5. Physiological Consequences –
   • Vascular smooth muscle – Relaxation leads to reduced systemic vascular resistance (afterload) and lower blood pressure.
   • Cardiac myocytes – Decreased contractility (negative inotropy) and reduced oxygen demand.
   • SA/AV nodes – Slowed phase 0 depolarisation slows heart rate and prolongs AV nodal conduction (more pronounced with non‑DHP agents).

Pharmacokinetic Highlights (Key Points for Exams)

• Absorption – Oral bioavailability is high for most agents; however, immediate‑release nifedipine undergoes extensive first‑pass metabolism, whereas amlodipine has a bioavailability of ~60 %.
• Distribution – Highly protein‑bound (≥ 90 % for amlodipine, verapamil).
• Metabolism – Primarily hepatic via CYP3A4; drugs that induce or inhibit CYP3A4 markedly alter plasma levels.
• Elimination – Amlodipine has a long half‑life (~ 35 h) allowing once‑daily dosing; diltiazem’s half‑life is ~ 3–5 h, requiring twice‑daily dosing.

Indications (Therapeutic Uses)

• Hypertension – DHP agents are first‑line for isolated systolic hypertension, especially in the elderly.
• Chronic Stable Angina – Both DHP (e.g., amlodipine) and non‑DHP (verapamil, diltiazem) reduce myocardial oxygen demand by decreasing afterload and contractility.
• Acute Coronary Syndromes – Intravenous nicardipine or clevidipine for rapid blood‑pressure control; oral DHP agents for long‑term management.
• Arrhythmias – Non‑DHP agents are preferred for supraventricular tachycardia (SVT), atrial fibrillation with rapid ventricular response, and for rate control in atrial flutter.
• Raynaud’s Phenomenon – DHP agents (nifedipine) improve digital blood flow by vasodilation.
• Hypertrophic Cardiomyopathy – Non‑DHP agents reduce outflow‑tract obstruction by decreasing contractility.

Contraindications (When NOT to Use)

• Severe hypotension (systolic BP < 90 mm Hg).
• Second‑ or third‑degree AV block without a pacemaker (especially non‑DHP).
• Sick sinus syndrome (non‑DHP).
• Severe left‑ventricular dysfunction (ejection fraction < 30 %) – caution with verapamil due to negative inotropy.
• Pregnancy – limited data; avoid unless benefits outweigh risks.

Adverse Effects (Common and Clinically Important)

High‑Yield Adverse‑Effect Points

• Peripheral edema is a hallmark of DHP agents; it results from preferential arteriolar dilation increasing hydrostatic pressure in capillaries.
• Constipation is a classic clue for verapamil overdose.
• Negative inotropy of non‑DHP agents can precipitate decompensated heart failure; monitor weight and symptoms.

Drug Interactions (Exam‑Relevant)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) ↑ plasma levels of both DHP and non‑DHP agents → risk of hypotension and bradycardia.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine) ↓ plasma levels → loss of therapeutic effect.
• Beta‑blockers – additive AV‑node slowing; useful in combination for rate control but increase risk of severe bradycardia.
• Digoxin – verapamil raises digoxin levels by reducing renal clearance; monitor serum digoxin.
• Statins metabolised by CYP3A4 (e.g., simvastatin) – concurrent CCBs increase statin concentrations → myopathy risk.

Monitoring Parameters

• Blood pressure and heart rate – check within 1 hour of dose initiation for IV therapy; weekly for oral titration.
• Electrocardiogram (ECG) – baseline and after dose adjustments when using non‑DHP agents.
• Signs of fluid overload – weight, peripheral edema, dyspnoea in patients with heart failure.
• Liver function tests – especially with diltiazem, which is hepatically metabolised.

Current Guideline Recommendations (2023‑2024)

• Hypertension – The 2023 ESC/ESH guideline recommends DHP CCBs (amlodipine, long‑acting nifedipine) as first‑line therapy in patients > 65 years or with isolated systolic hypertension.
• Chronic Stable Angina – 2024 ACC/AHA guideline places DHP CCBs (amlodipine, felodipine) as second‑line after β‑blockers; non‑DHP agents are preferred when heart rate control is also needed.
• Atrial Fibrillation Rate Control – 2023 AHA/ACC/HRS guideline recommends diltiazem or verapamil for patients without severe LV dysfunction; avoid in EF < 30 %.

Complications (Long‑Term Risks)

• Progressive peripheral edema may lead to skin breakdown and infection if untreated.
• Exacerbation of heart failure due to negative inotropic effect of non‑DHP agents; may require discontinuation and switch to DHP or other antihypertensives.
• Drug‑induced gingival overgrowth can impair oral hygiene and increase infection risk; requires dental evaluation.

High‑Yield Exam Points

• “DHP = Dilates peripheral vessels; Non‑DHP = Depresses cardiac conduction.”
• Peripheral edema → DHP; Constipation → Verapamil.
• Verapamil and diltiazem are contraindicated in second‑degree AV block without a pacemaker.
• Amlodipine’s long half‑life (~ 35 h) allows once‑daily dosing and reduces peak‑trough fluctuations.
• CYP3A4 inhibitors dramatically increase CCB levels; always ask about grapefruit juice.
• In acute hypertensive emergencies, IV nicardipine or clevidipine is preferred because of rapid titratability.

Practice questions

1. A 68‑year‑old man with isolated systolic hypertension is started on a calcium channel blocker. Which drug is most appropriate as first‑line therapy?
   Answer: Amlodipine — a long‑acting DHP that provides arterial vasodilation with minimal reflex tachycardia, recommended by ESC/ESH for elderly patients.

2. A patient with atrial fibrillation and a left‑ventricular ejection fraction of 28 % is being considered for rate control. Which calcium channel blocker is contraindicated?
   Answer: Verapamil — a non‑DHP with strong negative inotropic effect, contraindicated in severe LV dysfunction.

3. A 55‑year‑old woman on diltiazem for chronic angina develops severe constipation. Which of the following is the most likely explanation?
   Answer: Verapamil‑type adverse effect — constipation is a characteristic side effect of non‑DHP agents, especially verapamil, and can occur with diltiazem as well.

More in Pharmacology

AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.